Journal · Founder · 4 min
A letter from the laboratory: the year ahead.
Dr Judey opens 2026 with a short note on what the laboratory is working on, and what it has decided to leave alone.
Dr Judey · Biomedical Emporium®
3 January 2026
Every January the laboratory has one honest conversation with itself. What worked last year on real skin, what did not, and what deserves a second attempt. This year that conversation was shorter than usual, because most of what we shipped in 2025 held up.
Two things carry into 2026. First, the tissue-protective peptide system, which continues to test well across Fitzpatrick II to VI. Second, the discipline of leaving concentrations at the threshold where clinical benefit begins, not where marketing wishes it did. Higher is not better once tolerance drops. We keep stopping in the middle.
What we are leaving alone: fragrance, colourants, and every claim we cannot measure in number. Dermagate distributes the line unaltered in the Emirates. That contract with the shelf is the whole point.
Read next
The five ceramides your barrier already makes.
Healthy stratum corneum holds ceramides at a stoichiometric ratio. Match that ratio in the jar and you support what the skin was already trying to do.